Diogo Dias
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Diogo Dias has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Tero Aittokallio
Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
5 shared publications - Satu Mustjoki
Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Centre Helsinki, Helsinki, Finland
3 shared publications Aleksandr Ianevski
Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
2 shared publications- Aleksandr Ianevski
Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
2 shared publications - Jonas Bouhlal
CAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki University Hospital, Finland
2 shared publications - Olli Dufva
Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
2 shared publications
Latest Publications
- Open Access
Selective scoring of drug effects in multicellular co-culture systems
Multicellular co-culture screening reveals compound effects that depend on cell-cell interactions. Standard dose-response metrics fail to resolve effects that arise either from target-effector cell interactions or from non-specific toxic effects. Here, we developed Co-culture Efficacy Score (CES), a robust computational framework that enables systematic identification of compounds that selectively modulate cellular interactions in multicellular assays. CES framework supports both therapeutic scoring that penalizes direct effector cell toxicity, as well as a mechanistic discovery that estimates immunomodulatory effects by adjusting for effector cell responses. When screening 527 compounds across 10 hematological cancer models co-cultured with natural killer (NK) cells, CES distinguished co-culture-specific immunomodulatory effects from NK cell toxicity and cancer cell inhibitory responses, recovering systematic enhancer and inhibitory patterns. We further assessed CES robustness using higher-resolution validation screens and demonstrated its applicability to identify selective compounds in anti-CD19 CAR T-cell and antiviral host-pathogen screens. To facilitate its broad use, we implemented CES as an interactive web-application for quantitative analysis of compound responses in co-culture assays, providing a widely applicable scoring framework for cancer immunotherapy, antiviral screening and drug discovery.
Open AccessSelective scoring of drug effects in multicellular co-culture systems
Multicellular co-culture screening reveals compound effects that depend on cell-cell interactions. Standard dose-response metrics fail to resolve effects that arise either from target-effector cell interactions or from non-specific toxic effects. Here, we developed Co-culture Efficacy Score (CES), a robust computational framework that enables systematic identification of compounds that selectively modulate cellular interactions in multicellular assays. CES framework supports both therapeutic scoring that penalizes direct effector cell toxicity, as well as a mechanistic discovery that estimates immunomodulatory effects by adjusting for effector cell responses. When screening 527 compounds across 10 hematological cancer models co-cultured with natural killer (NK) cells, CES distinguished co-culture-specific immunomodulatory effects from NK cell toxicity and cancer cell inhibitory responses, recovering systematic enhancer and inhibitory patterns. We further assessed CES robustness using higher-resolution validation screens and demonstrated its applicability to identify selective compounds in anti-CD19 CAR T-cell and antiviral host-pathogen screens. To facilitate its broad use, we implemented CES as an interactive web-application for quantitative analysis of compound responses in co-culture assays, providing a widely applicable scoring framework for cancer immunotherapy, antiviral screening and drug discovery.
- Open Access
- 30 October 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (2) , 295-309
Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery
T-cell leukemias and lymphomas (TCL) form a heterogeneous group of rare and often aggressive malignancies. Because of the rarity and heterogeneity of TCL subtypes, clinical trials are challenging to conduct, making pharmacogenomic studies in cell line panels critical for the discovery of targeted therapeutics. The scarcity of data repositories with integrated multiomics and drug screening data hinders the preclinical evaluation of drug vulnerabilities and the identification of molecular markers predictive of responses to monotherapies and combinations. To address this gap, we conducted comprehensive pharmacogenomic profiling on a panel of 38 TCL cell lines, representing major clinical TCL subtypes to capture the molecular and phenotypic diversity. The TCL-38 multiomics data resource includes harmonized genetic, molecular, and epigenetic profiles, with comprehensive annotations and standardized drug response assessment of each cell line. This resource, together with machine learning predictions, was leveraged to identify TCL subtype–specific therapeutic vulnerabilities, including single-agent sensitivities and synergistic drug combinations, which were linked to genetic or epigenetic features as potential predictive biomarkers. This integrated and openly available resource (https://aittokallio.group/tcl38) could help advance the currently limited treatment options for patients with TCL. Significance: Integrated and harmonized multiomics analyses and drug screening across a heterogeneous panel of T-cell leukemias and lymphomas provide a resource to uncover drug targets and predictive biomarkers to improve patient outcomes.
- 30 October 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (2) , 295-309
Open AccessMultiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery
T-cell leukemias and lymphomas (TCL) form a heterogeneous group of rare and often aggressive malignancies. Because of the rarity and heterogeneity of TCL subtypes, clinical trials are challenging to conduct, making pharmacogenomic studies in cell line panels critical for the discovery of targeted therapeutics. The scarcity of data repositories with integrated multiomics and drug screening data hinders the preclinical evaluation of drug vulnerabilities and the identification of molecular markers predictive of responses to monotherapies and combinations. To address this gap, we conducted comprehensive pharmacogenomic profiling on a panel of 38 TCL cell lines, representing major clinical TCL subtypes to capture the molecular and phenotypic diversity. The TCL-38 multiomics data resource includes harmonized genetic, molecular, and epigenetic profiles, with comprehensive annotations and standardized drug response assessment of each cell line. This resource, together with machine learning predictions, was leveraged to identify TCL subtype–specific therapeutic vulnerabilities, including single-agent sensitivities and synergistic drug combinations, which were linked to genetic or epigenetic features as potential predictive biomarkers. This integrated and openly available resource (https://aittokallio.group/tcl38) could help advance the currently limited treatment options for patients with TCL. Significance: Integrated and harmonized multiomics analyses and drug screening across a heterogeneous panel of T-cell leukemias and lymphomas provide a resource to uncover drug targets and predictive biomarkers to improve patient outcomes.
- Open Access
A statistical framework for defining synergistic anticancer drug interactions
Synergistic drug combinations have the potential to delay drug resistance and improve clinical outcomes in patients with advanced cancers. However, current cell-based screens lack robust statistical assessment to identify significant synergistic interactions for downstream experimental or clinical validation. Leveraging a large-scale dataset that systematically evaluated more than 2,000 drug combinations across 125 pan-cancer cell lines, we established reference null distributions separately for various synergy metrics and cancer types. These data-driven reference distributions enable estimation of empirical p -values to assess the significance of observed drug combination effects, thereby standardizing synergy detection in future studies. The statistical evaluation confirmed key synergistic combinations and uncovered novel combination effects that met stringent statistical criteria, yet were overlooked in the original analyses. We revealed cell context-specific drug combination effects across tissue types and inherent differences in statistical behavior of the synergy metrics. To demonstrate the general applicability of our approach to smaller-scale studies, we applied it to evaluate the significance of combination effects in increasing smaller subsamples of an independent dataset. We provide a fast and statistically rigorous approach to detecting synergistic drug interactions in new combinatorial screens, thereby supporting more standardized drug combination discovery.
Open AccessA statistical framework for defining synergistic anticancer drug interactions
Synergistic drug combinations have the potential to delay drug resistance and improve clinical outcomes in patients with advanced cancers. However, current cell-based screens lack robust statistical assessment to identify significant synergistic interactions for downstream experimental or clinical validation. Leveraging a large-scale dataset that systematically evaluated more than 2,000 drug combinations across 125 pan-cancer cell lines, we established reference null distributions separately for various synergy metrics and cancer types. These data-driven reference distributions enable estimation of empirical p -values to assess the significance of observed drug combination effects, thereby standardizing synergy detection in future studies. The statistical evaluation confirmed key synergistic combinations and uncovered novel combination effects that met stringent statistical criteria, yet were overlooked in the original analyses. We revealed cell context-specific drug combination effects across tissue types and inherent differences in statistical behavior of the synergy metrics. To demonstrate the general applicability of our approach to smaller-scale studies, we applied it to evaluate the significance of combination effects in increasing smaller subsamples of an independent dataset. We provide a fast and statistically rigorous approach to detecting synergistic drug interactions in new combinatorial screens, thereby supporting more standardized drug combination discovery.
- Open Access
- 10 April 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (15) , 1670-1686
High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia
Natural killer (NK) cells have proven to be safe and effective immunotherapies, associated with favorable treatment responses in chronic myeloid leukemia (CML). Augmenting NK-cell function with oncological drugs could improve NK-cell–based immunotherapies. Here, we used a high-throughput drug screen consisting of >500 small-molecule compounds, to systematically evaluate the effects of oncological drugs on primary NK cells against CML cells. We identified second mitochondrially derived activator of caspases (SMAC) mimetics as potent enhancers of NK-cell cytotoxicity in both cell lines and primary patient samples. In contrast, several drug classes, including glucocorticoids and tyrosine kinase inhibitors such as dasatinib, inhibited NK-cell cytotoxicity. Single-cell RNA sequencing revealed drug-induced transcriptomic changes in both NK and target CML cells. SMAC mimetics upregulated NF-κB target genes in NK cells, potentially contributing to their enhanced cytotoxicity. Inhibitory drugs dexamethasone, dasatinib, and sotrastaurin prevented NK-cell transition to an activated state and suppressed the expression of interferon gamma (IFN-γ) by NK cells, thus preventing IFN-γ–mediated target cell transcriptomic response. In conclusion, we discovered that SMAC mimetics sensitize cancer cells to NK-cell–mediated killing, with potential clinical applications especially in patients with advanced phase CML.
- 10 April 2025
- Published by American Society of Hematology in Blood
- Vol. 145 (15) , 1670-1686
Open AccessHigh-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia
Natural killer (NK) cells have proven to be safe and effective immunotherapies, associated with favorable treatment responses in chronic myeloid leukemia (CML). Augmenting NK-cell function with oncological drugs could improve NK-cell–based immunotherapies. Here, we used a high-throughput drug screen consisting of >500 small-molecule compounds, to systematically evaluate the effects of oncological drugs on primary NK cells against CML cells. We identified second mitochondrially derived activator of caspases (SMAC) mimetics as potent enhancers of NK-cell cytotoxicity in both cell lines and primary patient samples. In contrast, several drug classes, including glucocorticoids and tyrosine kinase inhibitors such as dasatinib, inhibited NK-cell cytotoxicity. Single-cell RNA sequencing revealed drug-induced transcriptomic changes in both NK and target CML cells. SMAC mimetics upregulated NF-κB target genes in NK cells, potentially contributing to their enhanced cytotoxicity. Inhibitory drugs dexamethasone, dasatinib, and sotrastaurin prevented NK-cell transition to an activated state and suppressed the expression of interferon gamma (IFN-γ) by NK cells, thus preventing IFN-γ–mediated target cell transcriptomic response. In conclusion, we discovered that SMAC mimetics sensitize cancer cells to NK-cell–mediated killing, with potential clinical applications especially in patients with advanced phase CML.
- Open Access
- 4 March 2025
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 26 (2)
Scaling up drug combination surface prediction
Drug combinations are required to treat advanced cancers and other complex diseases. Compared with monotherapy, combination treatments can enhance efficacy and reduce toxicity by lowering the doses of single drugs—and there especially synergistic combinations are of interest. Since drug combination screening experiments are costly and time-consuming, reliable machine learning models are needed for prioritizing potential combinations for further studies. Most of the current machine learning models are based on scalar-valued approaches, which predict individual response values or synergy scores for drug combinations. We take a functional output prediction approach, in which full, continuous dose-response combination surfaces are predicted for each drug combination on the cell lines. We investigate the predictive power of the recently proposed comboKR method, which is based on a powerful input–output kernel regression technique and functional modeling of the response surface. In this work, we develop a scaled-up formulation of the comboKR, which also implements improved modeling choices: we (1) incorporate new modeling choices for the output drug combination response surfaces to the comboKR framework, and (2) propose a projected gradient descent method to solve the challenging pre-image problem that is traditionally solved with simple candidate set approaches. We provide thorough experimental analysis of comboKR 2.0 with three real-word datasets within various challenging experimental settings, including cases where drugs or cell lines have not been encountered in the training data. Our comparison with synergy score prediction methods further highlights the relevance of dose-response prediction approaches, instead of relying on simple scoring methods.
- 4 March 2025
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 26 (2)
Open AccessScaling up drug combination surface prediction
Drug combinations are required to treat advanced cancers and other complex diseases. Compared with monotherapy, combination treatments can enhance efficacy and reduce toxicity by lowering the doses of single drugs—and there especially synergistic combinations are of interest. Since drug combination screening experiments are costly and time-consuming, reliable machine learning models are needed for prioritizing potential combinations for further studies. Most of the current machine learning models are based on scalar-valued approaches, which predict individual response values or synergy scores for drug combinations. We take a functional output prediction approach, in which full, continuous dose-response combination surfaces are predicted for each drug combination on the cell lines. We investigate the predictive power of the recently proposed comboKR method, which is based on a powerful input–output kernel regression technique and functional modeling of the response surface. In this work, we develop a scaled-up formulation of the comboKR, which also implements improved modeling choices: we (1) incorporate new modeling choices for the output drug combination response surfaces to the comboKR framework, and (2) propose a projected gradient descent method to solve the challenging pre-image problem that is traditionally solved with simple candidate set approaches. We provide thorough experimental analysis of comboKR 2.0 with three real-word datasets within various challenging experimental settings, including cases where drugs or cell lines have not been encountered in the training data. Our comparison with synergy score prediction methods further highlights the relevance of dose-response prediction approaches, instead of relying on simple scoring methods.